Volume 11, Number 6—June 2005
Research
Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs
John M. Stelling*†
, Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
, Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§Table 3
Nonsusceptibility rates of Escherichia coli by region, 2001*
| Drug | North America | Latin America | Northern Europe | Southern Europe + South Africa | Western Pacific |
|---|---|---|---|---|---|
| Ampicillin | |||||
| 20%–40% | Canada (35%) | Sweden (31%) | Italy (40%) | Japan (30%) | |
| 40%–60% | United States (44%) | Argentina, Brazil, Chile, Venezuela (54%–57%) | Belgium, France, Germany, Ireland, Switzerland, United Kingdom (46%–57%) | Greece (51%) | Australia, Singapore (50%–54%) |
| >60% | Colombia, Mexico (71%–76%) | Poland (62%–84%) | Israel, South Africa, Spain, Turkey (62%–84%) | Hong Kong, Philippines, Taiwan (64%–82%) | |
| Trimethoprim/sulfamethoxazole | |||||
| 0%–20% | Italy (19%) | Australia, Japan (11%–17%) | |||
| 20%–40% | Canada, United States (20%–23%) | Argentina, Chile (28%–39%) | Belgium, Ireland, Poland, Sweden, Switzerland, United Kingdom (20%–31%) | France, Greece, Spain (20%–31%) | |
| 40%–60% | Brazil, Colombia, Mexico, Venezuela (51%–57%) | Germany (40%) | Israel, South Africa, Turkey (42%–59%) | Hong Kong, Philippines, Singapore, Taiwan (40%–60%) | |
| Ceftazidime | |||||
| ≤5% | Canada, United States (MYS 3%, SEN 1%–2%) | Brazil, Chile (SEN 2%–4%) | Belgium, Czech Republic, Germany, Ireland, Poland, Sweden, Switzerland, United Kingdom (MYS 0%–3%, SEN 0%–3%) | Greece (SEN), France, South Africa Spain, Turkey (SEN) (MYS 4%, SEN 0%–5%) | Australia, Hong Kong, Japan, Singapore (MYS 0%, SEN 2%–3%) |
| >5% | Argentina, Colombia, Mexico, Venezuela (MYS 7%–13%, SEN 6%–11%) | Greece (MYS), Israel, Italy, Turkey (MYS) (MYS 6%–11%, SEN 6%–8%) | Philippines, Taiwan, Thailand (MYS 19%, SEN 6%) | ||
| Ciprofloxacin | |||||
| ≤10% | United States, Canada (MYS 2%–10%, SEN 7%–9%) | Argentina (MYS), Brazil (SEN) (MYS 4%, SEN 10%) | Belgium (MYS), Czech Republic, Ireland, Poland, Sweden, Switzerland, United Kingdom (MYS 0%–7%, SEN 0%–9%) | France, South Africa (SEN 2%–6%) | Australia, Japan (MYS 0%, SEN 0%–2%) |
| >10% | Argentina (SEN), Brazil (MYS), Chile, Colombia, Mexico, Venezuela (MYS 14%–17%, SEN 12%–26%) | Belgium (SEN), Germany (MYS 18%, SEN 14%–26%) | Greece, Israel, Italy, Spain, Turkey (MYS 14%–39%, SEN 14%–30%) | Hong Kong, Philippines, Singapore, Taiwan (SEN 12%–31%) | |
*For countries with <30 isolates in 2001, data from 2000 and 2001 were combined. Ranges of nonsusceptibility rates are indicated in parentheses. For ampicillin and trimethoprim/sulfamethoxazole, data are only available from the SENTRY system. MYS, MYSTIC; SEN, SENTRY.
